Baudax Bio (BXRX) Misses Q2 EPS by 1c

Baudax Bio (NASDAQ: BXRX) reported Q2 EPS of ($0.21), $0.01 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $201 thousand versus the consensus estimate of $470 thousand.

For earnings history and earnings-related data on Baudax Bio (BXRX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49